Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine-Reference-Cited by-同舟云学术

Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine

Published:2012-09 Issue:9 Volume:18 Page:1415-1421
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Platzbecker Uwe,Schetelig Johannes,Finke Jürgen,Trenschel Rudolf,Scott Bart L.,Kobbe Guido,Schaefer-Eckart Kerstin,Bornhäuser Martin,Itzykson Raphael,Germing Ulrich,Beelen Dietrich,Ehninger Gerhard,Fenaux Pierre,Deeg H. Joachim,Adès Lionel

Funder

NIH

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference30 articles.

1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

2. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

3. Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS);Deeg;Hematology Am Soc Hematol Educ Program,2005

4. Optimizing outcome of MDS patients posttransplantation;Sockel;Expert Rev Hematol,2011

5. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia;Bertz;J Clin Oncol,2003

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome;Bone Marrow Transplantation;2024-07-09

2. Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee;Blood;2024-05-30

3. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms;Experimental Hematology;2024-02

4. Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome Patients;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

5. Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes;The Cancer Journal;2023-05